Precision BioSciences (DTIL) Reports Publication of ARCUS In Vivo Gene Editing as a Promising Therapeutic Approach to Cure Chronic Hepatitis B Infection streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
- Accepted abstracts to be presented as oral presentations and posters highlight preclinical development progress for ARCUS® gene editing therapiesDURHAM, N.C. (BUSINESS WIRE) $DTIL #ARCUS Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic.